Amgen and Bushu Pharma Announce Expanded Supply Chain Partnership across Japan and Asia-Pacific...

Bushu Pharmaceuticals

2021/11/24 16:00

KAWAGOE, Japan, Nov. 24, 2021 /Kyodo JBN/ --

Bushu Pharmaceuticals Ltd.

Amgen and Bushu Pharma Announce Expanded Supply Chain Partnership across Japan and Asia-Pacific Region

 

- “Gateway to Asia” Contract Manufacturing Organization (CMO) Agreement to Double Volume of Drugs Produced for Amgen by Bushu Pharma -

 

Bushu Pharmaceuticals Ltd. (“Bushu Pharma”) has agreed on an expanded partnership with Amgen Inc. and Amgen K.K. to provide its “Gateway to Asia” service to four countries across the Asia-Pacific region as Amgen’s contract manufacturing organization (CMO).

 

Logo: https://kyodonewsprwire.jp/prwfile/release/M106205/202111093084/_prw_PI1fl_cWK7OADe.jpg

 

An integral factor in Amgen’s business growth in Japan, Bushu Pharma has partnered with Amgen since 2016 to assure pharmaceutical drug product supply continuity and quality excellence for Amgen patients in Japan. Further reinforcing the value of this partnership, Amgen has awarded Bushu Pharma the expanded Gateway to Asia contract for supply to Amgen’s biggest markets, including mainland China, Taiwan and South Korea. The decision is expected to double the current volume of Amgen products being manufactured and packaged by Bushu Pharma -- including Repatha, Evenity, Prolia, and Xgeva. The scope of the work under Bushu Pharma’s Gateway to Asia services will be to assemble, label, package and inspect the products for those markets, with the first supply of these drugs set to commence this year.

For the joint press release with Amgen, please refer:

https://www.bushu-pharma.com/en/amgen-and-bushu-pharma-announcement/

 

Tadao Takano, Chief Operational Officer and President at Bushu Pharma, said, “We are pleased to have built a strong partnership through successful launches of Amgen’s four (Repatha, Evenity, Blincyto, and Aimovig) innovative drugs in Japan and scaled production to match the growing patient needs. The new Gateway to Asia services will enable further effectiveness in importing bulk products to Japan for quality inspection, labeling, packaging and distribution throughout Japan and Asia-Pacific.”

 

In addition to this agreement with Amgen, Bushu Pharma has also recently established its Kazo Packaging Center and agreed on a business alliance with Suzuken Co., Ltd. through which the company will provide comprehensive support for new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market. Bushu Pharma’s Gateway to Asia service offers global manufacturers like Amgen the chance to efficiently enter and grow their sales in Japan and across the Asia-Pacific region.

 

About Bushu Pharmaceuticals Ltd., Japan:

Bushu Pharma was established in August 1998 as an independent pharmaceutical contract manufacturer. Bushu Pharma, capitalized at 1 billion yen, carries out pharmaceutical drug product contract manufacturing and packaging of clinical trials and commercial products in accordance with the latest cGMP standards. Through the utilization of know-how and the latest industry information, Bushu Pharma prides itself on being able to offer added-value solutions to its customers.

 

For more information about Bushu Pharma, visit www.bushu-pharma.com/en/

Gateway to Asia details: https://www.bushu-pharma.com/en/services/scm/gateway-to-asia/

 

The company’s white paper (PDF) on the Gateway to Asia solution is also available here:

https://kyodonewsprwire.jp/attach/202111093084-O1-7SKkAoi6.pdf

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

プレスリリース添付画像

Bushu Pharma

| Small | Normal |
| Original |

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

このプレスリリースを配信した企業・団体

  • ※購読している企業の確認や削除はWebプッシュ通知設定画面で行なってください
  • SNSでも最新のプレスリリース情報をいち早く配信中